Oxidative modification and antioxidant protection of human low **density lipoprotein at high and** low **oxygen partial pressures**

Akira Hatta and Balz Freil

Whitaker Cardiovascular Institute, Boston University School of Medicine, **80** East Concord Street, **W601,** Boston, MA **02118**

Abstract Oxidative modification of low density lipoprotein (LDL) in the subendothelial space of the arterial wall has been implicated **as** an initial process in atherosclerosis. In vitro studies of LDL oxidation are usually done at ambient oxygen partial pressure $(PQ_2;$ approximately 160 torr, or 21% \widetilde{Q}_2), which is considerably higher than arterial tissue $PO₂$ (30-70) torr, and **as** low **as 20** torr, or **2.5% 02,** in atherosclerotic lesions). In addition, β-carotene acts as an efficient free radical scavenger only at low $PO₂$. Therefore, we investigated the effects of high (20%) and low (2%) $PO₂$ on the kinetics of LDL oxidation, and the effectiveness of β -carotene compared to other physiological antioxidants in preventing LDL oxidation. At low $PO₂$, the rate of $Cu²⁺$ -induced oxidative modification of LDL was lower than at high PO_2 . Furthermore, at high $PO₂$ there was a distinct lag phase preceding the propagation phase of lipid peroxidation in Cu²⁺-exposed LDL, as measured by cholesteryl ester hydroperoxide formation; in contrast, there appeared to be no distinct lipid peroxidation lag phase in LDL incubated with Cu^{2+} at low PO_2 . Elevating α -tocopherol levels in LDL about 5-fold resulted in significant antioxidant protection: the lipid peroxidation lag phase at high PQ_2 increased by 45% (from 58 \pm 11 to 84 \pm 3 min, $P \le$ **0.05),** and the initial rate **(0-1** h) of lipid hydroperoxide formation at low PO_2 was reduced by 52% (from $11.\overline{6} \pm 1.9$ to 5.6 ± 1.0 nmol/mg LDL protein/h, $P \le 0.01$). In contrast, increasing LDL β -carotene levels about 6-fold did not inhibit LDL oxidation at either *PO*₂. Most remarkably, low concentrations of ascorbic acid (30 μ _M) drastically reduced LDL oxidation, regardless of **PO**₂: the lipid peroxidation lag phase at high PQ_2 increased more than 7-fold (from 46 ± 11 min to > 360 min , $P \leq 0.001$), and at low PQ_2 no lipid hydroperoxides could be detected for at least 6 h of incubation. **In** These results show that at low physiological *PO₂*, Cu²⁺-induced LDL oxidation occurs at a significantly lower rate than at ambient **PO₂**. At both high and low **PO₂**, β-carotene cannot inhibit LDL oxidation, whereas α -tocopherol has a moderate protective effect, and low physiological concentrations of ascorbic acid very strongly suppress LDL oxidation.-Hatta, A., and **B.** Frei. Oxidative modification and antioxidant protection of human low density lipoprotein at high and low oxygen partial pressures. J. Lipid *Res.* **1995. 36: 2383-2393.**

Oxidatively modified low density lipoprotein (LDL) has a number of biologic properties that are atherogenic. For example, oxidatively modified LDL facilitates foam cell formation from macrophages, is chemotactic for monocytes, T-lymphocytes, and smooth muscle cells, and is cytotoxic **(1-3).** Based on these biologic properties, LDL oxidation has been implicated **as** a causal factor in the development of human atherosclerosis **(1, 3). As** an important corollary of the "oxidative modification hypothesis of atherosclerosis" **(l),** antioxidants that can prevent LDL oxidation may act as anti-atherogens **(2).** In the blood stream, LDL oxidation is effectively prevented by numerous water-soluble antioxidants and metal-binding proteins, including ascorbic acid, uric acid, bilirubin, transferrin, and albumin **(4,5).** Ascorbic acid appears to be particularly potent in preventing lipid peroxidation in plasma **(4).** Therefore, it has been postulated that clinically relevant LDL oxidation occurs in the subendothelial space of the arterial wall, where the concentration of some of these antioxidants may be lower than in plasma **(1).** LDL itself contains a number of lipid-soluble antioxidants, such **as** tocopherols, carotenoids, and ubiquinols (6, 7). **As** the lipoprotein content of α -tocopherol and β -carotene is dependent on dietary intake and can be increased by supplementation, much interest in the scientific literature has been directed towards the protection of LDL by these antioxidants.

Numerous studies using in vivo or in vitro supplemen-

JOURNAL OF LIPID RESEARCH

Supplementary key words atherosclerosis modified lipoproteins oxygen tension • lipid peroxidation • vitamin C • vitamin E • β-carotene

Abbreviations: AAPH, 2,2'-azobis(2-amidinopropane) dihydrochloride; αt-LDL, α-tocopherol-supplemented LDL; βc-LDL, β-carotenesupplemented LDL; CEOOH, cholesteryl ester hydroperoxides; ct-LDL, control LDL; LDL, low density lipoprotein; PO₂, oxygen partial pressure; PBS, phosphate-buffered saline; HPLC, high **performance liquid chromatography.**

^{&#}x27;To whom correspondence should be addressed.

tation have found that α -tocopherol, the most abundant antioxidant in LDL, has significant protective effects against LDL oxidation $(2, 8-11)$. In contrast, the effects of β -carotene on LDL oxidation are less clear (2, 10-15). Some epidemiological studies have shown that increased intake of &carotene or increased adipose tissue B-carotene levels in humans are associated with reduced **risk** of coronary artery disease (16-18). However, in vivo supplementation of humans with β -carotene does not result in increased resistance of plasma-derived LDL to ex vivo oxidation (10-13), and several in vitro studies also have failed to demonstrate an antioxidant effect of β -carotene against LDL oxidation (2, 12). These experiments with β -carotene-supplemented LDL, with one exception (13), were carried out under air, i.e., at an oxygen partial pressure (PO_2) of about 160 torr $(21\%$ O_2). At such high PO₂ levels, β-carotene can be oxidized to &carotene peroxide and act **as** a pro-oxidant (19-21). However, the $PO₂$ in the subendothelial space of the arterial wall, where LDL oxidation likely occurs (1,3), is considerably lower than in air. Measurements in the arterial wall range from about 30 to 70 torr $(4-10\% \text{ O}_2)$ depending on the location (22); after the onset of atherogenesis, the $PO₂$ in the subendothelial space may drop even further, corresponding to about 2.5% O₂ (23). At these lower **PO₂** levels, LDL oxidation may be slowed considerably, and β -carotene may act as an efficient free radical scavenger.

Therefore, in this study, we investigated LDL oxidation and antioxidant protection at high and low $PO₂$. The effects of β -carotene under these conditions were studied and compared to the effects of α -tocopherol and ascorbic acid, two other physiological antioxidants. Our data reveal dramatic differences in the kinetics of LDL oxidation and the effects of the various antioxidants tested, depending on the $PO₂$.

MATERIALS AND METHODS

Chemicals

Ascorbic acid, reduced glutathione, d, l - α -tocopherol, $CuSO₄ \cdot 5H₂O$, isoluminol, and microperoxidase were purchased from Sigma Chemical Co. p-Carotene (alltrans) was purchased from Fluka, and Chelex 100 resin from Bio-Rad. Ebselen and 15-hydroperoxy-eicosatetraen-l-oic acid were obtained from Cayman Chemical Co., and Sephadex G-25 was from Pharmacia, Sweden. All other chemicals were of the highest purity commercially available.

LDL isolation

LDL isolation was performed as described by Retsky, Freeman, and Frei (24). Briefly, about 30 ml of blood

was collected from a normolipidemic healthy subject using heparinized vacutainer tubes (sodium heparin 286 USP units/l5 ml blood). Plasma was obtained by centrifugation and then filtered through a Sephadex G-25 column to remove ascorbic acid and uric acid (24). The plasma density was adjusted to 1.21 g/ml , and a discontinuous gradient WAS established by layering the plasma under a 0.154 **M** NaCl solution. The tubes were spun at 80,000 rpm at 7°C for 45 min in an NVT-90 rotor, using a Beckman ultracentrifuge L8-80M (25). LDL was collected from the tubes by sideways puncturing the yellow LDL band. We have shown previously that LDL prepared in this manner contains < 3% albumin contamination (6). Protein concentration in the LDL solutions was measured by the method of Lowry et al. (26), using bovine serum albumin as a standard. Isolated LDL was used immediately for experiments or was stored (not longer than 18 h) under N_2 and at 4°C until used in experiments.

Incubation **of LDL** at **20%** and **2%** *Pop*

To examine the effects of PO₂ on LDL oxidation, we designed a system to keep the O_2 concentration in the LDL solutions constant, **as** shown in **Fig. 1.** Chelextreated phosphate-buffered saline (PBS; 136 mM NaC1, 2.6 mM KCl, 1.4 mM KH_2PO_4 , 8.0 mM Na_2HPO_4 , pH 7.4) containing 20% or 2% O₂ was prepared by bubbling for 30 min with 20% O₂/80% N₂ or 2% O₂/98% N₂ (Matheson Gas Products, Boston, MA). LDL and Cu²⁺ were then added to these PBS solutions and the $PO₂$ was maintained constant by performing incubations under a constant gas flow $(10-25 \text{ ml/min})$ at 37° C. All gas mixtures used for LDL incubations were first bubbled through distilled water at 37°C to saturate the gas and to avoid concentrating the LDL solutions (Fig. 1). The $O₂$ concentration in the reaction solutions under the 20% and 2% *02* gas stream, respectively, were maintained at 7.1 ± 1.4 and 0.4 ± 0.2 ppm (mean \pm SD, n = 9) for 24 h, **as** measured with a dissolved oxygen sensor (DO-6, Presto-Tek, Los Angeles, CA). The expected dissolved *02* concentration in distilled water at 37°C under air is 6.9 ppm.

Preparation **of** a-tocopherol- and β-carotene-supplemented LDL

Stock solutions (162.5 μ l) of 4.5 mM α -tocopherol in ethanol or 12.8 mm β -carotene in tetrahydrofuran were added to 6.5 ml of plasma and incubated at 37°C under N_2 . After incubation for 3 h (α -tocopherol) or 10 min $(\beta$ -carotene), LDL was isolated as described above. Control LDL was prepared from plasma (6.5 mi) incubated with 162.5 µl of the respective vehicles. LDL isolated from B-carotene- or tetrahydrofuran-treated plasma was incubated for 30 min at 37°C with 0.02 mM ebselen and

Fig. 1. System for LDL incubation under controlled PO₂ conditions. The O₂ concentration in the LDL incubations was kept constant by **blowing 20% O₂/80% N₂ or 2% O₂/98% N₂ gas at a flow rate of 10-25** ml/min on the surface of the LDL solution. The gas was first bubbled **through distilled water. The tubes containing the water and the LDL incubations were sealed with a rubber stopper (A) and placed in a thermostatted waterbath (37'C). The needle through which the** *gas* **entered the tube containing the LDL solution was connected via a T-valve (B) to a 1-ml syringe. For sample withdrawal, the valve was switched to the position connected to the syringe and the needle was lowered into the LDL solution. Immediately after sample withdrawal, the needle was retracted to the position indicated in the figure and valve B was switched back to the position connected to the** *gas* **inlet.**

3 mM reduced glutathione to eliminate lipid hydroperoxides formed during the treatment (12). After the incubation, ebselen and glutathione were removed from the LDL solutions by passage through three successive PD-10 columns (Pharmacia) equilibrated and eluted with PBS (12).

LDL oxidation

LDL oxidation was initiated by the addition of $2.5 \mu M$ $Cu²⁺$ to 0.2 mg LDL protein/ml in PBS, followed by incubation at 37°C for up to 24 h. The oxidation of LDL at 20% and 2% PO₂ was carried out in the incubation system described above (Fig. 1). LDL oxidation was characterized by consumption of endogenous a-tocopherol and β-carotene, formation of cholesteryl ester hydroperoxides (CEOOH), and increased anodic electrophoretic mobility of LDL on agarose gels (27).

Some of the LDL preparations used in this study contained residual amounts of KBr. In separate experiments it was determined that the presence of KBr in LDL incubations does not affect the kinetics of $Cu²⁺$ -induced lipid peroxidation, **as** assessed by the length of the lag phase and the rate of conjugated diene formation (234 nm absorbance) during the lag and propagation phases (12).

Determination of CEOOH in LDL

To determine the concentration of CEOOH, 250-µl aliquots were withdrawn from the LDL incubations at regular time intervals during the first 6 h of incubation. Aliquots were mixed with 250 µl methanol to precipitate proteins, and neutral lipids were extracted with 2.5 ml hexane that had been washed with water to remove trace amounts of lipid hydroperoxides (28). After shaking vigorously and spinning at 2,000 rpm for 10 min, 2.0 ml of the hexane phase was collected and stored under N_2 gas at -2O'C until analysis (within 72 h). Determination of CEOOH was performed by HPLC using an LC-18 column (25 cm **x** 4.6 mm i.d., Supelco) with post-column chemiluminescence detection (28).

Determination of antioxidants

Aliquots (250 µl) were withdrawn from LDL incubations and the concentrations of antioxidants were determined by HPLC with electrochemical detection (27,29). The HPLC system was calibrated daily using fresh solutions of $d, l-\alpha$ -tocopherol or β -carotene in ethanol or ascorbic acid in metaphosphoric acid.

Agarose gel electrophoresis of LDL

Gel electrophoresis was performed using the Beckman Paragon electrophoresis system following the manufacturer's instructions. Gels were stained with Sudan Black B.

Data analysis

The length of the lipid peroxidation lag phase in LDL incubated at 20% PO₂ was determined by drawing a tangent to the steepest section of the CEOOH formation curve during the propagation phase and extrapolating to the abscissa; the intersection of the tangent with the abscissa was measured and is presented in the paper **as** lag phase (min). Lag phases and initial antioxidant levels in control and supplemented LDL preparations were compared using the paired Student's t-test or the Mann-Whitney **U** test where appropriate. Time-dependent changes in antioxidant levels and CEOOH concentrations in LDL were compared using repeated-measures **ANOVA.** Statistical significance was accepted if the null hypothesis was rejected at the *P* = 0.05 level.

EMS

RESULTS

LDL oxidation by Cu*+ under ambient, 20%, and 2% PO²

In order to investigate the effects of $PO₂$ on the kinetics of LDL oxidation, freshly isolated human LDL (0.2 mg protein/ml, in PBS) was incubated at 37°C with

Fig. 2. The effects of PO₂ on Cu²⁺-induced antioxidant consumption and lipid peroxidation in LDL. LDL **(0.2** mg of protein/ml, in PBS) was incubated at 37°C with 2.5 μ m Cu²⁺ at ambient (A), 20% (B), or 2% **PO₂** (C). At the indicated times, aliquots were withdrawn and the concentrations of α -tocopherol (\square), β -carotene (\diamond), and cholesteryl ester hydroperoxides (CEOOH, 0) were determined. One experiment representative **of** two is shown.

Fig. 3. The effects of **PO₂** on Cu²⁺-induced lipid peroxidation in LDL. LDL **(0.2** mg of protein/ml, in PBS) was incubated at 37'C with **2.5** μ _M Cu²⁺ at 20% (O) or 2% PO_2 (\bullet). At the indicated times, aliquots were withdrawn and the concentrations of cholesteryl ester hydroperoxides (CEOOH) were determined. Data represent the mean **f** SEM **of ten independent experiments.** $P \le 0.001$ **for the difference between** the **two** timecourse curves **(0-6** h), using repeated-measures ANOVA.

2.5 μ M Cu²⁺ at ambient, 20%, or 2% PO₂. At ambient PO_2 (Fig. 2A), α -tocopherol and β -carotene levels in LDL were depleted within 2.5 h of incubation and CEOOH levels increased slowly during this time. After this initial lag phase, the propagation phase of lipid peroxidation ensued, followed by the decomposition of lipid hydroperoxides (Fig. 2A). Incubation of LDL at 20% PO₂ in the apparatus shown in Fig. 1 caused an acceleration of LDL oxidation; the propagation of CEOOH formation occurred earlier than at ambient PO_2 with a lag phase of between 1.0 and 1.5 h (Fig. 2B and **Fig.** 3). Interestingly,

Fig. 4. The effects of PO₂ on electrophoretic mobility of Cu²⁺-exposed LDL. LDL **was** incubated **as** described in the legend of Fig. **2** and aliquots were withdrawn at the indicated times for agarose gel electrophoresis. Lanes from left to right show LDL before incubation (native LDL, lane **1)** and LDL incubated at ambient (amb.), **20%.** and **2%** *PO?,* respectively, after *6* h (lanes **2-4)** and **24** h incubation (lanes **5-7).** One experiment representative of two is shown.

OURNAL OF LIPID RESEARCH

SBMB

Fig. **5.** The effects of a-tocopherol supplementation on Cu2+-induced lipid peroxidation in LDL at high and low **pa.** Control LDL (open symbols) and a-tocopherol-supplemented LDL (closed symbols) **(0.2** mg of protein/ml, in PBS) were incubated at 37°C with **2.5 p~** Cu2' at **20%** (A) or **2% POz (B). At** the indicated times, aliquots were withdrawn and the concentrations of a-tocopherol (0, **m)** and cholesteryl ester hydroperoxides (CEOOH; 0, *0)* were determined. Data represent the mean **f** SEM of four independent experiments. **P* ⁼ **0.056** versus a-tocopherol-supplemented LDL over the first 3 h of incubation **(A),** and *tP* < 0.01 versus a-tocopherol-supplemented LDL over **6** h of incubation (B), using repeated-measures **ANOVA.**

at **2% Po2** there was no clearly distinguishable lag phase of lipid peroxidation (Figs. 2C and 3). Although the initial rates (0-30 min) of Cu²⁺-induced CEOOH formation in LDL were similar at 2% and 20% PO₂ (8.1 ± 1.6) and 10.8 ± 2.2 nmol/mg protein/h, respectively; mean \pm SD, n = 10), the time course of lipid peroxidation over 6 h of incubation was significantly different ($P \le 0.001$) (Fig. 3). Despite these marked differences in lipid peroxidation, the rates of α -tocopherol and β -carotene consumption in LDL were similar at ambient, **20%,** and 2% PO_2 (Fig. 2).

The results on lipid peroxidation were also reflected in the oxidative modification of LDL as assessed by agarose gel electrophoresis. The anodic electrophoretic mobility of LDL incubated for 6 h with Cu²⁺ at 20% PO₂ was greater than that of LDL incubated under air, while the mobility of LDL incubated at 2% PO₂ was only moderately increased (Fig. **4).** After **24** h of incubation, the electrophoretic mobility of LDL incubated under all three conditions had increased substantially, with LDL incubated at 20% **PO**₂ being slightly more oxidized than LDL incubated at ambient or 2% PO_{2} (Fig. 4).

Effects **of** a-tocopherol supplementation **on LDL** PCarotene **(3)** 67f3 **60f9 0.29 oxidation at 20% and 2% PO₂**

In order to investigate the effects of α -tocopherol on LDL oxidation at 20% and 2% PO₂, LDL was supplemerited in vitro by incubating plasma with an excess of α -tocopherol prior to LDL isolation. This method leads to effective incorporation of a-tocopherol into LDL **(30).** The changes in a-tocopherol concentration and the effect of a-tocopherol supplementation on CEOOH

generation in LDL incubated with Cu²⁺ at 20% PO₂ are shown in Fig. **5A.** a-Tocopherol-supplemented LDL (α t-LDL) contained about 5 times more α -tocopherol (P < 0.02) than control LDL isolated from vehicle-treated plasma (ct-LDL). This increase in α -tocopherol content was associated with a delay of Cu2+-induced CEOOH generation in LDL. Specifically, the lipid peroxidation lag phase preceding the onset of the propagation phase was significantly increased ($P \le 0.05$) in αt -LDL compared to ct-LDL (Table **l),** and the difference in the time course of CEOOH formation during the first 3 h of incubation was almost statistically significant $(P= 0.056,$ Fig. 5A).

a-Tocopherol content and CEOOH formation in at-LDL and ct-LDL incubated with Cu^{2+} at 2% PO₂ are

TABLE 1. Length of the lipid peroxidation lag phase in control
and antioxidant-supplemented LDL incubated with Cu²⁺ at 20% rO_2

	Lag Phase (min), mean \pm SD		
	Control LDL	Supplemented LDL	P Value
α -Tocopherol (4)	58 ± 11	84 ± 3	0.03
β -Carotene (3)	67 ± 3	60 ± 9	0.29
Ascorbic acid (3)	46 ± 11	> 360	< 0.001

LDL (0.2 mg of protein/ml, in PBS) was incubated at 37°C with 2.5 μ_M Cu²⁺ at 2G% _PO₂ and formation of cholesteryl ester hydroperoxides was determined. The **data** are presented in Figs. **5A,** 7A, and **9A,** and further experimental details can be found in the legends of these figures. The length of the lipid peroxidation **lag** phase preceding the Onset of the Propagation Phase was determined **as** described in Materials and Methods. The numbers in parentheses represent the number of experiments. *P* values were determined using the paired Student's t-test.

Fig. **6. The** effects of a-tocopherol supplementation on electrophoretic mobility of Cu²⁺-exposed LDL at high and low *PO*₂. Control LDL and α -tocopherol-supplemented LDL were incubated as described in the legend of Fig. **5** and aliquots were withdrawn at the indicated times for agarose gel electrophoresis. Lanes from left to right show control LDL (-) and **a-tocopherol-supplemented** LDL (+) before incubation (lanes **1** and **2),** after 6 h incubation at **2%** (lanes 3 and **4)** and **20% PO2** (lanes *5* and **6),** and after **24** h incubation at **2%** $(\text{lanes } 7 \text{ and } 8)$ and $20\% \text{ PQ}_2$ (lanes 9 and 10). One experiment representative of four is shown.

shown in Fig. 5B. *As* observed above (Figs. **2C** and 3), the CEOOH levels in ct-LDL increased steadily over the first 6 h of incubation with apparently no distinct lag phase. α -Tocopherol levels in ct-LDL and α t-LDL were depleted within 1.5 and **2.0** h of incubation, respectively (Fig. 5B), very similar to the rates of α -tocopherol consumption at 20% PO_2 (Fig. 5A). At 2% PO_2 , there was significantly less lipid peroxidation $(P < 0.01)$ in αt -LDL compared to ct-LDL (Fig. 5B), **as** also reflected by the initial rates **(0-1** h) of CEOOH generation, which were 5.6 ± 1.0 and 11.6 ± 1.9 nmol/mg protein / h (mean \pm SD, $n = 4$ for αt -LDL and ct-LDL, respectively $(P \le 0.01)$.

Although a-tocopherol supplementation significantly suppressed lipid peroxidation at both *PO2* levels, oxidative modification of LDL as assessed by agarose gel electrophoresis was only moderately affected. The mobility of at-LDL was lower compared to ct-LDL after 6 h of incubation with Cu^{2+} at 20% PO₂, but no difference in the mobility was observed after **24** h **(Fig. 6).** At **2%** *pop,* the mobility of at-LDL was identical to ct-LDL both after 6 and **24** h of incubation (Fig. 6).

Effects of β-carotene supplementation on LDL oxidation at 20% and 2% **PO₂**
Time

Plasma LDL was supplemented with β -carotene in vitro as described above for α -tocopherol, leading to an increase in LDL β-carotene content of about 6-fold $(P < 0.02)$ compared to ct-LDL. α -Tocopherol levels in β -carotene-supplemented LDL (β c-LDL) and ct-LDL were not significantly different $(9.2 \pm 2.6 \text{ and } 8.5 \pm 3.0 \text{)}$ nmol/mg protein, respectively; mean \pm SD, n = 3). pc-LDL and ct-LDL were incubated with **Cu2+** at **20%** or 2% PO₂. Interestingly, although the same ct-LDL and β c-LDL preparations were used in these experiments, the initial β-carotene levels were substantially lower in LDL incubated at 20% compared to 2% PO₂. This may have resulted from a rapid initial loss of β -carotene in the first sample withdrawn from the LDL incubations.

j3-Carotene levels in pc-LDL were depleted within **4** h of incubation with Cu^{2+} at 20% PO_2 (Fig. 7A), while a small amount of β -carotene remained after 6 h of incubation at 2% PO₂ (Fig. 7B). Lipid peroxidation in LDL Downloaded from www.jlr.org by guest, on June 17, 2012

Downloaded from www.jlr.org by guest, on June 17, 2012

Fig. 7. The effects of β -carotene supplementation on Cu²⁺-induced lipid peroxidation in LDL at high and low **PO₂.** Control LDL (open symbols) and β-carotene-supplemented LDL (closed symbols) (0.2 mg of protein/ml, in PBS) were incubated at 37°C with 2.5 µm Cu²⁺ at 20% (A) or 2% PO₂ (B). At the indicated times, aliquots were withdrawn and the concentrations of β -carotene (\Box, \blacksquare) and cholesteryl ester hydroperoxides (CEOOH; \bigcirc , \bigcirc) were determined. Data represent the mean **f** SEM of three independent experiments.

BMB

Fig. **6. The** effects of a-tocopherol supplementation on electrophoretic mobility of Cu²⁺-exposed LDL at high and low *PO*₂. Control LDL and α -tocopherol-supplemented LDL were incubated as described in the legend of Fig. **5** and aliquots were withdrawn at the indicated times for agarose gel electrophoresis. Lanes from left to right show control LDL (-) and **a-tocopherol-supplemented** LDL (+) before incubation (lanes **1** and **2),** after 6 h incubation at **2%** (lanes 3 and **4)** and **20% PO2** (lanes *5* and **6),** and after **24** h incubation at **2%** $(\text{lanes } 7 \text{ and } 8)$ and $20\% \text{ PQ}_2$ (lanes 9 and 10). One experiment representative of four is shown.

shown in Fig. 5B. *As* observed above (Figs. **2C** and 3), the CEOOH levels in ct-LDL increased steadily over the first 6 h of incubation with apparently no distinct lag phase. α -Tocopherol levels in ct-LDL and α t-LDL were depleted within 1.5 and **2.0** h of incubation, respectively (Fig. 5B), very similar to the rates of α -tocopherol consumption at 20% PO_2 (Fig. 5A). At 2% PO_2 , there was significantly less lipid peroxidation $(P < 0.01)$ in αt -LDL compared to ct-LDL (Fig. 5B), **as** also reflected by the initial rates **(0-1** h) of CEOOH generation, which were 5.6 ± 1.0 and 11.6 ± 1.9 nmol/mg protein / h (mean \pm SD, $n = 4$ for αt -LDL and ct-LDL, respectively $(P \le 0.01)$.

Although a-tocopherol supplementation significantly suppressed lipid peroxidation at both *PO2* levels, oxidative modification of LDL as assessed by agarose gel electrophoresis was only moderately affected. The mobility of at-LDL was lower compared to ct-LDL after 6 h of incubation with Cu^{2+} at 20% PO₂, but no difference in the mobility was observed after **24** h **(Fig. 6).** At **2%** *pop,* the mobility of at-LDL was identical to ct-LDL both after 6 and **24** h of incubation (Fig. 6).

Effects of β-carotene supplementation on LDL oxidation at 20% and 2% **PO₂**
Time

Plasma LDL was supplemented with β -carotene in vitro as described above for α -tocopherol, leading to an increase in LDL β-carotene content of about 6-fold $(P < 0.02)$ compared to ct-LDL. α -Tocopherol levels in β -carotene-supplemented LDL (β c-LDL) and ct-LDL were not significantly different $(9.2 \pm 2.6 \text{ and } 8.5 \pm 3.0 \text{)}$ nmol/mg protein, respectively; mean \pm SD, n = 3). pc-LDL and ct-LDL were incubated with **Cu2+** at **20%** or 2% PO₂. Interestingly, although the same ct-LDL and β c-LDL preparations were used in these experiments, the initial β-carotene levels were substantially lower in LDL incubated at 20% compared to 2% PO₂. This may have resulted from a rapid initial loss of β -carotene in the first sample withdrawn from the LDL incubations.

j3-Carotene levels in pc-LDL were depleted within **4** h of incubation with Cu^{2+} at 20% PO_2 (Fig. 7A), while a small amount of β -carotene remained after 6 h of incubation at 2% PO₂ (Fig. 7B). Lipid peroxidation in LDL Downloaded from www.jlr.org by guest, on June 17, 2012

Downloaded from www.jlr.org by guest, on June 17, 2012

Fig. 7. The effects of β -carotene supplementation on Cu²⁺-induced lipid peroxidation in LDL at high and low **PO₂.** Control LDL (open symbols) and β-carotene-supplemented LDL (closed symbols) (0.2 mg of protein/ml, in PBS) were incubated at 37°C with 2.5 µm Cu²⁺ at 20% (A) or 2% PO₂ (B). At the indicated times, aliquots were withdrawn and the concentrations of β -carotene (\Box, \blacksquare) and cholesteryl ester hydroperoxides (CEOOH; \bigcirc , \bigcirc) were determined. Data represent the mean **f** SEM of three independent experiments.

BMB

BMB

OURNAL OF LIPID RESEARCH

Fig. 10. The effects of ascorbic acid on electrophoretic mobility of Cu?*-exposed LDL at high and low Po?. LDL was incubated in the absence or presence of ascorbic acid as described in the legend of Fig. 9 and aliquots were withdrawn at the indicated times for agarose gel electrophoresis. Lanes from left to right show LDL incubated in the absence (-) **or presence of ascorbic acid** (+) **before incubation (lanes 1** and 2), after 6 h incubation at 2% (lanes 3 and 4) and 20% PO₂ (lanes **5 and 6), and after 24 h incubation at 2% (lanes 7 and 8) and 20%** pop **(lanes 9 and 10). One experiment representative of three is shown.**

acid was no longer different from ct-LDL, but LDL incubated at 2% PO₂ was still strongly protected by ascorbic acid (Fig. 10).

DISCUSSION

The aims of this study were to investigate oxidative modification of LDL and antioxidant effects of α -tocopherol, β -carotene, and ascorbic acid at an O_2 partial pressure relevant to (patho)physiological conditions in the arterial wall. We first examined the effects of PO₂ on Cu2+-induced oxidation of normal (unsupplemented) LDL. Interestingly, the rate of LDL oxidation was increased at 20% compared to ambient PO₂. This acceleration of LDL oxidation may be related to the different incubation systems used, i.e., LDL incubated under a constant gas flow of 20% **02/80% N2** (Fig. 1) versus LDL incubated under air (about 21% O₂, 78% N₂, and 1% argon) in an open system without gas flow. The former compared to the latter conditions may lead to a more enhanced and sustained concentration of dissolved *⁰²* in the incubations and thus faster LDL oxidation. Oxidative modification of LDL was substantially slower at 2% **PO₂** compared to ambient or 20% **PO**₂. These latter findings are consistent with data reported by Reaven et **al. (13)** and indicate that the *02* concentration is a rate-limiting factor for LDL oxidation at low $PO₂$. This result is not unexpected, as lipid peroxidation is an initial step of LDL oxidation **(1,** 2, 7) and lipid peroxidation involves the incorporation of *02* into polyunsaturated fatty acids, i.e., is an $O₂$ -dependent process. In contrast, the rates of α -tocopherol and β -carotene consumption in LDL were independent of $PO₂$ (see Figs. 2, *5,* and **7),** indicating that these antioxidants may be consumed by mechanisms other than scavenging of reactive oxygen species and lipid-derived oxygen-centered radicals. For example, at lower oxygen partial pressures, where peroxidation reactions are suppressed (Fig. **3),** the LDLassociated antioxidants may primarily react with carbon-centered lipid radicals.

Interestingly, under the incubation conditions used, Cu^{2+} -induced lipid peroxidation in LDL at 2% PO₂ occurred without a clearly distinguishable lag phase. Such a lipid peroxidation lag phase preceding the propagation phase is commonly observed when LDL is oxidized at ambient or **20% Po2** and has been attributed to the inhibition of lipid peroxidation by LDL-associated antioxidants (7) . Although α -tocopherol is by far the most abundant known antioxidant in human LDL, we have shown recently that the tocopherol content of LDL only explains about one third of the length of the lipid peroxidation lag phase in Cu2+-exposed LDL **(31).** Likewise, Esterbauer et al. (7) have concluded that only about one third of the lag phase in LDL can be attributed to vitamin E, whereas two thirds must be due to other, largely unknown factors. It may be that these unknown factors, in contrast to α -tocopherol, are ineffective at inhibiting LDL lipid peroxidation at 2% PO₂, thus explaining the apparent lack of a lag phase under these conditions. Alternatively, in LDL incubated at 2% $PO₂$, the rate of lipid peroxidation may not increase after the endogenous antioxidants and other protective factors have been exhausted because the *02* concentration is rate-limiting (see above). In fact, the initial rates of lipid peroxidation in LDL incubated at 2% and 20% PO₂ were very similar and only later, during the "propagation" phase, was there a greatly increased rate of lipid peroxidation at 20% compared to 2% PO₂ (see Fig. 3). This accelerated formation of lipid hydroperoxides at 20% $PO₂$ was accompanied by their earlier decomposition and, consequently, a more rapid increase in the electrophoretic mobility of LDL (Fig. **4).** The latter is most likely due to apolipoprotein B modification by lipid hydrop eroxide breakdown products (1, 2, 7). Our data, therefore, suggest that investigations of LDL oxidation at ambient PO_2 may not reflect the kinetics of LDL oxidation at physiological $PO₂$ in the subendothelial space of the arterial wall.

We also investigated the protective effects of selected physiological antioxidants against LDL oxidation at high and low PO_2 . At 2% PO_2 , α -tocopherol supplementation

reduced the initial rate of lipid peroxidation in LDL by more than 50% but the increase in electrophoretic mobility was not suppressed. Similarly, at 20% PO₂, α -tocopherol supplementation led to an increase in the lipid peroxidation lag phase, consistent with published data (7,8, 10,30), but electrophoretic mobility was only moderately affected. We did not, however, observe a pro-oxidant effect of α -tocopherol supplementation on Cu2+-induced LDL oxidation under our air incubation conditions. Bowry, Ingold, and Stocker (32), using the same method for lipid hydroperoxide analysis **as** used in the present study, reported that α -tocopherol supplementation increased, rather than decreased, the initial rate of lipid peroxidation in LDL exposed to aqueous peroxyl radicals generated by 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH). In support of these data, we recently reported (31) that the tocopherol content of LDL is inversely correlated with the lipid peroxidation lag phase when LDL is exposed to AAPH. In contrast, we found the opposite to be true for Cu^{2+} induced LDL oxidation, i.e., the higher the lipid-standardized tocopherol content of LDL, the longer the lipid peroxidation lag phase. Taken together, our data indicate that under the specific incubation conditions used by us α -tocopherol exerts a pro-oxidant effect in AAPHexposed LDL, in contrast to $Cu²⁺$ -exposed LDL, where a-tocopherol inhibits lipid peroxidation both at high and low $PO₂$. However, α -tocopherol supplementation appears to offer only moderate or no protection at 20% and 2% PO₂, respectively, against Cu²⁺-induced increases in electrophoretic mobility of LDL. As increased electrophoretic mobility of LDL correlates well with macrophage degradation and thus increased atherogenicity of LDL (1, 2, 24), these data suggest that α -tocopherol may have little effect on atherogenic modification of LDL in the arterial wall.

Unlike α -tocopherol, β -carotene had no measurable effect on Cu2+-induced lipid peroxidation in LDL at 20% PO₂. These findings are consistent with published data showing that LDL isolated from subjects given β -carotene supplements is not more resistant to $Cu²⁺$ -induced oxidation than LDL isolated from placebo-treated control subjects (10-13). We have recently confirmed and extended these data by showing that both in vitro and in vivo supplementation with β -carotene does not inhibit LDL lipid peroxidation induced by $Cu²⁺$ or AAPH (12). However, in almost all the above cited studies, LDL was incubated under ambient $PO₂$. As β -carotene acts as an efficient antioxidant only at low physiological PO₂ (19, 21), it is conceivable that these studies on LDL oxidation are of limited relevance to physiological conditions and may have overlooked a possible protective effect of β -carotene. Reaven et al. (13) recently addressed this question by incubating LDL from β -carotene-supplemented subjects (containing 19-fold higher levels of β-carotene than LDL isolated from placebo-treated control subjects) at ambient, 4%, and 2% PO₂. No increased resistance to oxidation of **B**-carotene-enriched LDL compared to control LDL was observed under all incubation conditions (13). Our data using in vitro supplementation with β -carotene (resulting in a 6-fold increased LDL fi-carotene content) and incubation at 20% and 2% **PO**₂ are in agreement with the observations by Reaven and colleagues (13). Therefore, the protective effects of β carotene against cardiovascular disease (16-18) are most likely not mediated by increased protection of LDL against oxidation in the arterial wall. Alternative mechanisms by which B-carotene may act are reduced capacity of arterial wall cells to modify LDL (13,33), preservation of endothelial vasodilator function (34), and increased serum high density lipoprotein levels (35).

By far the most dramatic protective effects against Cu2+-induced lipid peroxidation and oxidative modification of LDL both at 20% and 2% *Pop* in the present study were observed in the presence of ascorbic acid. The concentration of ascorbic acid used was only 30 μ M, i.e., was at the low end of the physiological concentration range in human plasma $(30-150 \mu)$ (5, 29). Using this low concentration of ascorbic acid, the lag phase of lipid peroxidation in Cu²⁺-exposed LDL at 20% PO₂ was extended more than 7-fold. and the initial rate of lipid peroxidation at 2% PO₂ was reduced by 100%. Interestingly, ascorbic acid was oxidized rapidly and was not present throughout most of the time during which LDL was protected against oxidation. We have shown previously that at ambient **Po2** ascorbic acid oxidation product(s) prevent LDL oxidation, possibly due to selective destruction of metal-binding sites on apolipoprotein B (24). Based on the present findings, these mechanism(s) appear to be relevant at physiological $PO₂$ as well.

Our data, therefore, suggest that LDL in the subendothelial space of the arterial wall should be strongly protected against metal iondependent oxidative modification by ascorbic acid, while α -tocopherol has a moderate effect and β -carotene is ineffectual. Thus, the question arises of whether ascorbic acid is present in the interstitial fluid of the subendothelial space in concentrations sufficient to prevent LDL oxidation. We have recently used a model of human interstitial fluid and shown that in this fluid the ascorbic acid concentration is as high as in plasma (36). It has been shown that in plasma lipid peroxidation is effectively prevented by endogenous ascorbic acid (4,5,29). Nevertheless, it may be that ascorbic acid becomes depleted in microenvironments of the arterial wall, where it cannot be replaced readily by passive diffusion from the blood stream. In fact, it is conceivable that the same factors that inhibit

 $O₂$ diffusion into the arterial wall, resulting in low arterial **PO₂** levels (22, 23), also limit ascorbic acid diffusion. Therefore, it will be important to investigate whether in vivo ascorbic acid supplementation can inhibit the formation **of** oxidized LDL in the arterial wall and thus the atherosclerotic process.

This work was supported by National Institutes of Healthgrant **HL-49954,** and funds from Tsumura & Co., Japan. We thank John F. Keaney, Jr., for help with the statistical analysis and critical reading of the manuscript.

Manuscript received 16 February 1995 and in revised form 17 July 1995.

REFERENCES

- **1.** Steinberg, D. **S.,** Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. **1989.** Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity. *N. EngLJ. Med.* **320 915-924.**
- **2.** Keaney, J. F., Jr., and B. Frei. **1994.** Antioxidant protection of lowdensity Lipoprotein and its role in the prevention of atherosclerotic vascular disease. *In* Natural Antioxidants in Human Health and Disease. B. Frei, editor. Academic Press, San Diego. **303-35 1.**
- **3.** Schwartz, **C.** J., and A. J. Valente. **1994.** The pathogenesis of atherosclerosis. *In* Natural Antioxidants in Human Health and Disease. B. Frei, editor. Academic Press, San Diego. **287-302.**
- **4.** Frei, B., R. Stocker, and B. N. Ames. **1988.** Antioxidant defenses and lipid peroxidation in human blood plasma. *hc.* Natl. *Acad. Sci. USA. 85* **9748-9752.**
- **5.** Stocker, **R.,** and B. Frei. **1991.** Endogenous antioxidant defenses in human blood plasma. *In* Oxidative Stress: Oxidants and Antioxidants. H. Sies, editor. Academic Press, London. **213-243.**
- **6.** Stocker, R., V. W. Bowry, and B. Frei. **1991.** Ubiquinol-10 protects human low density lipoprotein more eficiently against lipid peroxidation than does a-tocopherol. *Proc.* Natl. *Acad. SEi. USA. 88* **1646-1650.**
- **7.** Esterbauer, H., J. Gebicki, H. Puhl, and G. Jurgens. **1992.** The role of lipid peroxidation and antioxidants in the oxidative modification of LDL. *Free Rad. Biol. Med.* **13: 341 -390.**
- 8. Dieber-Rotheneder, M., H. Puhl, G. Waeg, G. Striegl, and H. Esterbauer. **1991.** Effect of **oral** supplementation with $D-A-tocomperol$ on the vitamin E content of human low density lipoproteins and resistance to oxidation. J. *Lipid Res.* **52: 1325-1332.**
- **9.** Jialal, I., and **S.** M. Grundy. **1992.** Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low density lipoprotein. J. *Lipid Res.* **³³ 899-906.**
- **10.** Princen, H. M. G., G. van Poppel, C. Vogelezang, R. Buytenhek, and F. J. Kok. **1992.** Supplementation with vitamin E but not β -carotene in vivo protects low density lipoprotein from lipid peroxidation in vitro. Effect of cigarette smoking. *A~fmimch. Thromb.* **12: 554-562.**
- **11.** Reaven, P. D., A. Khouw, W. F. Beltz, S. Parthasarathy, and J. L. Witztum. **1993.** Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by β-carotene. Arterioscler. Thromb. 13: 590-600.
- **12.** Gaziano, J. M., A. Hatta, M. Flynn, E. J. Johnson, N. I. Krinsky, P. M. Ridker, C. H. Hennekens, and B. Frei. **1995.** Supplementation with Pcarotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. *Atherosclerosis.* **112: 187-195.**
- **13.** Reaven, P. D., E. Ferguson, M. Navab, and F. L. Powell. **1994.** Susceptibility of human LDL to oxidative modification. Effects of variations in @carotene concentration and oxygen tension. Arterioscler. Thromb. 14: 1162-1169.
- **14.** Jialal, **I., E.** P. Norkus, **L.** Cristol, and S. M. Grundy. **1991.** @Carotene inhibits the oxidative modification of low-density lipoprotein. *Biochim. Biophys. Acta.* **1086: 134- 138.**
- **15.** Lavy, A., A. Ben Amotz, and M. Aviram. **1993.** Preferential inhibition of LDL oxidation by the all-trans isomer of p-carotene in comparison with **9-cis** @carotene. *Eur. J. Clin. Chem. Clin. Biochem.* **31: 83-90.**
- **16.** Gaziano, J. M., J. E. Manson, P. M. Ridker, J. E. Buring, and C. H. Hennekens. **1990.** Beta-carotene therapy for chronic stable angina. *Circulation.* **82:** A **0796.**
- **17.** Kardinaal, A. F. M., F. J. Kok, J. Ringstad, J. Gomez-Aracena,V. P. Mazaev, L. Kohlmeier, B. C. Martin,A. Aro, J. D. Kark, M. Delgado-Rodriguez, R. A. Riemersma, P. van't Veer, J. K. Huttunen, and J. M. Martin-Moreno. **1993.** Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC study. *Lancet.* **342: 1379- 1384.**
- **18.** Gaziano, J. M., J. E. Manson, and C. H. Hennekens. **1994.** Natural antioxidants and cardiovascular disease: observational epidemiologic studies and randomized trials. *In* Natural Antioxidants in Human Health and Disease. B. Frei, editor. Academic Press, San Diego. **387-409.**
- **19. Burton, G. W., and K. U. Ingold. 1984. β-Carotene: an** unusual type of lipid antioxidant. *Science.* **224 569-573.**
- **20.** Liebler, D. C. **1993.** Antioxidant reactions of carotenoids. *Ann. N.Y. Acad, Sci.* **691: 20-31.**
- **21.** Vile, G. F., and C. C. Winterbourn. **1988.** Inhibition of adriamycin-promoted microsomal lipid peroxidation by β -carotene, α -tocopherol and retinol at high and low oxygen partial pressures. *FEBS Lett.* **238: 953-356.**
- **22.** Crawford, D. W., and D. H. Blankenhorn. **1991.** Arterial wall oxygenation, oxyradicals, and atherosclerosis. *Ath~OSCl~osis.* **89 97-108.**
- **23.** Hajar, D. **P.,** I. C. Farber, and S. C. Smith. **1988.** Oxygen tension within the arterial wall: relationship to altered bioenergetic metabolism and lipid accumulation. *Arch. Biochm. Biophys. 262:* **375-380.**
- **24.** Retsky, K. **L.,** M. W. Freeman, and B. Frei. **1993.** Ascorbic acid oxidation product(s) protect human low density lipoprotein against atherogenic modification. Anti- rather than prooxidant activity of vitamin C in the presence of transition metal i0ns.J. *Biol. Chem.* **268: 1304-1309.**
- **25.** Chung, B. H., J. P. Segrest, M. J. Ray, J. D. Brunzell, J. E. Hokanson, R. M. Krauss, K. Beaudrie, and J. T. Cone. **1986.** Single vertical spin density gradient ultracentrifugation. *Methods Enzymol.* **128: 181-209.**
- **26.** Lowry, **0.** H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. **1951.** Protein measurement with the Folin phenol reagent.J *Biol. Chem.* **193: 265-275.**
- **27.** Lynch, **S. M.,** J. D. Morrow, L. J. Roberts **II,** and B. Frei. **1994.** Formation of **non-cyclooxygenasederived** prostanoids (F_2 -isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. *J. Clin. Invest.* **93: 998-1004.**
- **28.** Frei, B., Y. Yamamoto, D. Nictas, and B. N. **Ames. 1988.** Evaluation of an isoluminol chemiluminescence assay for

OURNAL OF LIPID RESEARCH

JOURNAL OF LIPID RESEARCH

the detection of hydroperoxides in human blood plasma. *Anal. Biochem.* **175: 120-130.**

- **29.** Frei, B., L. England, and B. N. Ames. **1989.** Ascorbate is an outstanding antioxidant in human blood plasma. *Roc. Natl. Acad. Sci. USA. 86* **6377-6381.**
- **30.** Esterbauer, H., M. Dieber-Rotheneder, G. *Striegl,* and G. Waeg. **1991.** Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am. *J. Clin. Nutr.* 53: 314S-321S.
- **31.** Frei, B., and J. M. *Gaziano.* **1993.** Content of antioxidants, preformed lipid hydroperoxides, and cholesterol **as** predictors of the susceptibility of human LDL to metal iondependent and -independent 0xidation.J. Lipid *Res.* **34 2 135-2145.**
- **32.** Bowry, V. W., K. **U.** Ingold, and R. Stocker. **1992.** Vitamin **E** in human lowdensity lipoprotein. When and how this antioxidant becomes a pro-oxidant. *Biochem. J.* 288: **341-344.**
- **33.** Navab, M., **S.** S. Imes, S. Y. Hama, G. P. Hough, L. A. **Ross,** R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater,

H. **Laks,** and A. M. Fogelman. **1991.** Monocyte transmigration induced by modification of low density lipopre tein in cocdtures of human aortic wall cells is due **to** induction of monocyte chemotactic protein **1** synthesis and is abolished by high density lipoprotein. *J. Clin. Invest. 88:* **2039-2046.**

- **34.** Keaney, J. F., Jr., J. **M.** Gaziano, A. Xu, 8. Frei, J. Curran-Celentano, G. T. Shwaery, J. Loscalzo, and J. A. Vita. **1993.** Dietary antioxidants preserve endotheliumdependent vessel relaxation in cholesterol-fed rabbits. *Proc. Natl. A~ad SCi. USA.* **90: 1 1880-1 1884.**
- **35.** Gaffney, P. T., **R** L. Buttenshaw, G. A. Lovell, W. J. Kerswill, and M. Ward. 1990. **B-Carotene supplementa**tion **raises** serum HDL-cholesterol. *Aut. N.* Z. *J. Med.* **40: 1-365.**
- **36.** Dabbagh, A. J., and B. Frei. **1995.** Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems.J. *Clin. Invest.* **96: 1958-1966.**